Avalo Therapeutics (AVTX) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $7.5 million.
- Avalo Therapeutics' Accumulated Expenses rose 661.17% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 661.17%. This contributed to the annual value of $6.3 million for FY2024, which is 5141.42% up from last year.
- According to the latest figures from Q3 2025, Avalo Therapeutics' Accumulated Expenses is $7.5 million, which was up 661.17% from $6.5 million recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Accumulated Expenses ranged from a high of $17.6 million in Q2 2021 and a low of $4.2 million during Q4 2023
- In the last 5 years, Avalo Therapeutics' Accumulated Expenses had a median value of $7.9 million in 2024 and averaged $10.0 million.
- In the last 5 years, Avalo Therapeutics' Accumulated Expenses surged by 17145.39% in 2021 and then tumbled by 6842.74% in 2023.
- Quarter analysis of 5 years shows Avalo Therapeutics' Accumulated Expenses stood at $16.5 million in 2021, then fell by 20.01% to $13.2 million in 2022, then crashed by 68.43% to $4.2 million in 2023, then surged by 51.41% to $6.3 million in 2024, then grew by 18.7% to $7.5 million in 2025.
- Its Accumulated Expenses stands at $7.5 million for Q3 2025, versus $6.5 million for Q2 2025 and $4.6 million for Q1 2025.